CD274 and neoplasm: To evaluate tumor retention and targeting ability of TKNP and anti‐PD‐L1‐TKNP, In Vivo Imaging System (IVIS) was used, and tumor retention of the nanoparticles was evaluated at 0, 0.5, 6, 12, and 24 h.